
Miguel L Fribourg-Casajuana, PhD
About Me
Miguel Fribourg-Casajuana, PhD, is an engineer and immunologist. His lab focuses on multidisciplinary approaches that combine theoretical and experimental techniques to study cellular signaling in the context of organ transplant immunology with the aim to guide clinical intervention. Dr. Fribourg-Casajuana earned a PhD in Signal Processing from the Polytechnical University in Madrid (UPM), and a PhD in biomedical sciences in a cell-signaling at an electrophysiology lab at the Icahn School of Medicine at Mount Sinai in New York. He did five years of postdoctoral training in systems biology in the field of immunology, where he honed his skills in experimental techniques and computational analyses in functional genomics and studied the effects of type I interferons in early viral infections. Current research interests in the lab include the study of the role of interferon-beta in transplant and the development of new biosensors to monitor regulatory T cell (Treg) activity and function.
Language
English
Position
ASSISTANT PROFESSOR | Pharmacological Sciences
Multi-Disciplinary Training Areas
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Disease Mechanisms and Therapeutics (DMT), Immunology [IMM]
Publications
Selected Publications
- Correction to: Gamma-Glutamyl Cysteine Ligase Activity as a Proxy for Human T Cell Function and Drug-Induced Immunosuppression (Advanced Science, (2025), 12, 37, 10.1002/advs.202501179). Francisco Fueyo-González, Carmen Salto-Giron, Mehek Ningoo, Laura Espinar-Barranco, Rafael Salto, Jose Manuel Paredes, Rosario Herranz, Angel Orte, Miguel Fribourg, Juan A. González-Vera. Advanced Science
- Gamma-Glutamyl Cysteine Ligase Activity as a Proxy for Human T Cell Function and Drug-Induced Immunosuppression. Francisco Fueyo-González, Carmen Salto-Giron, Mehek Ningoo, Laura Espinar-Barranco, Rafael Salto, Jose Manuel Paredes, Rosario Herranz, Angel Orte, Miguel Fribourg, Juan A. González-Vera. Advanced Science
- Metabolic dysregulation in regulatory T cells from patients with immune-mediated glomerular diseases. Johan Noble, Zuzana Macek-Jilkova, Philippe Saas, Paolo Malvezzi, Miguel Fribourg, Leonardo V. Riella, Mario Perez Arnedo, Joaquin Manrique, Paolo Cravedi. Journal of Nephrology
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Fribourg-Casajuana during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Editorial Services
- Elsevier
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.